Skip to main content
Erschienen in:

01.06.2019 | Case report

Eculizumab

Severe chronic hepatocellular cholestasis secondary to off-label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mauras M, et al. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab? Pediatric Nephrology 34: 1289-1293, No. 7, Jul 2019. Available from: URL: http://doi.org/10.1007/s00467-019-04234-6 - France Mauras M, et al. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab? Pediatric Nephrology 34: 1289-1293, No. 7, Jul 2019. Available from: URL: http://​doi.​org/​10.​1007/​s00467-019-04234-6 - France
Metadaten
Titel
Eculizumab
Severe chronic hepatocellular cholestasis secondary to off-label use: 3 case reports
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63709-6